Contract research and development

Evidence that holds up, from first dose to approval.

DM Lab designs and runs clinical programmes for biotech and specialty pharma teams, with the data rigour regulators expect.

Explore services Talk to a scientist
Abstract illustration of a cell count on a haemocytometer grid
Fig. 1Cell density count, haemocytometer grid, 10× objective

Our record

Studies delivered
150+
Phase I to IV
Countries with active sites
24
EU, US and APAC
Sponsors who return
96%
3-year average
Median database lock
18 days
After last patient visit

Services

Support at every stage of the development lifecycle

Engage us for a single workstream or the full programme. Each team reports into one accountable project lead.

  • Clinical development

    Protocol design, site selection and trial management for Phase I to IV studies.

  • Bioanalytics

    Validated LC-MS/MS and ligand-binding assays with GLP-compliant reporting.

  • Market access & HEOR

    Real-world evidence and health-economic models that support reimbursement.

  • Medicinal chemistry

    Hit-to-lead and lead optimisation, with structure-activity reporting each sprint.

Approach

Scientific judgement, built into the operating model

Every study is led by a scientist with hands-on experience in the indication. They stay with the programme from protocol to final report, so decisions are made by people who understand the data.

  • One accountable scientific lead per programme
  • Risk-based monitoring, reviewed weekly
  • Raw data available to sponsors in real time
How we work
Fig. 2Interference pattern, two coherent sources

Sponsors

What sponsors say

Their scientific lead caught a dosing issue in the protocol before first patient in. That saved us a substantial amendment.

Client nameVP Clinical Operations, oncology biotech

We had live access to the data for the whole study. Database lock came three weeks ahead of plan.

Client nameHead of Biostatistics, specialty pharma

Sustainability

Lower-impact trials, with no loss of evidence

Decentralised visits, local labs and paperless monitoring cut the footprint of a typical Phase II study by around a third.

Read our commitment

Insights

Notes from the lab and the clinic

All articles